From: Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni
Prevalence in SAC prior to treatment | Model | Model-recommended treatment strategy for achieving EPHP | Model-recommended treatment strategy for achieving EOT after the achievement of EPHP |
---|---|---|---|
Low (< 10%) | ICL | 75% SAC for 2–4 years | 75% SAC and 30% adults for 8–9 years |
Moderate (10–50%) | ICL | 75% SAC for 5–7 years | 75% SAC and 55% adults for 9–10 years |
SCHISTOX | 75% SAC for 6–8 years | 75% SAC and 55% adults for 7 years | |
High (≥ 50%) | ICL | 90% SAC and 45% adults for 5–6 years (baseline prevalence below 60% SAC + 63% adults) 95% SAC and 85% adults for 10 years (baseline prevalence: 71% SAC + 72% adults) | 75% SAC and 55% adults for 7–8 years (baseline prevalence below 60% SAC + 63% adults) 85% SAC and 75% adults for 9 years (baseline prevalence: 71% SAC + 72% adults) |
SCHISTOX | 90% SAC and 45% adults for 4–8 years (baseline prevalence below 76% SAC + 64% adults) 95% SAC and 85% adults for 8 years (baseline prevalence: 79% SAC + 72% adults) | 75% SAC and 55% adults for 6–7 years (baseline prevalence below 76% SAC + 64% adults) 85% SAC and 75% adults for 8 years (baseline prevalence: 79% SAC + 72% adults) |